AlphAIAlphAI — Financial news for AI agents
stocktitan.netSEP 41 min read$EMBC

Embecta (NASDAQ: EMBC) director files to sell $36,891 in stock

Embecta Corp. (EMBC) director Morris Milton Mayo filed a Form 144 to sell 6,293 shares, worth $36,891, acquired as director compensation on February 7, 2024. The sale will be executed through RBC Capital Markets on NASDAQ.

Original reporting
stocktitan.net
Published Sep 4, 2026, 7:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 5, 2026, 9:03 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$EMBC
Neutral
low confidence
Mentioned
$EMBC
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$EMBCNeutralLow
01

Why it matters

The filing discloses a modest insider disposition, unlikely to move the stock significantly.

02

Market read

Limited relevance; small insider sale with minimal market effect.

03

What to watch

Potential upcoming dilution or secondary offering could amplify impact.

Relevance 4/10Novelty 3/10Timing: reported Sep 4 2026

Background

Form 144 is a notice of proposed sale of restricted securities, filed with the SEC.

Company-level read

Ticker impact

$EMBCNeutralLow confidence
Context

Form 144 filing shows director Morris Milton Mayo intends to sell 6,293 shares worth $36,891.

Expected impact

Potential modest dip of 0.5-1% if market reacts.

Evidence & confidence

Sale size is small relative to float; no material impact expected.

Market effects

Sector

None

Regional

None

Global

None

Counterpoint

What could challenge this read

Even small insider sales can signal concerns; watch for further disposals.

Key entities

  • Director
    Morris Milton Mayo

    Embecta director filing to sell shares.

Read at source← All news

Related articles

AUG 17
$EMBCMedAI 8/10

Embecta (EMBC) Q3 2026 Earnings Call Transcript

Embecta (NASDAQ:EMBC) held its FY2026 Q3 earnings call. Revenue was $271.7M, down 8.1% YoY, with U.S. revenue down 24.6% and international up 11.5% on Owen Mumford strength. Adjusted EPS was $0.56. Free cash flow was $41M. FY2026 guidance: revenue $1.015B-$1.035B, adjusted EPS $1.80-$1.90, margin 23.5%-24%.

aol.com10 min
AUG 14
$EMBCHighAI 9/10

Embecta (EMBC) Q3 2026 Earnings Call Transcript

Embecta (EMBC) reported Q3 FY2026 revenue of $271.7 million, down 8.1% YoY, with U.S. revenue down 24.6% and international revenue up 11.5%. Adjusted EPS was $0.56. The company raised FY2026 adjusted operating margin guidance to 23.5% to 24% and EPS to $1.80 to $1.90, reaffirming revenue guidance of $1.015B to $1.035B.

fool.com6 min
AUG 7
$EMBCMed

Embecta Corp. Reports Third Quarter Fiscal 2026 Financial Results

Embecta Corp. (EMBC) filed an SEC Form 8-K — Results of Operations and Financial Condition. FOR IMMEDIATE RELEASE Embecta Corp. Reports Third Quarter Fiscal 2026 Financial Results PARSIPPANY, N.J., Aug 7, 2026 (GLOBE NEWSWIRE) – Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three and n

SEC EDGAR 8-K7 min
OCT 24
$CMPXMedAI 8/10

Compass Therapeutics publishes tovecimig trial results in JCO

Compass Therapeutics (NASDAQ:CMPX) published Phase 2/3 trial results for tovecimig in the Journal of Clinical Oncology. The study met primary and secondary endpoints, showing improved response rates and progression-free survival in advanced biliary tract cancer patients compared to paclitaxel alone. However, overall survival showed no significant difference, and adverse events were higher in the combination arm. Tovecimig remains investigational.

investing.com2 min